Author:
Ruigómez Ana,Plana Estel,Gilsenan Alicia,Fortuny Joan,Cainzos-Achirica Miguel,Flynn Robert W. V.,MacDonald Thomas M.,Garcia-Rodriguez Luis,Ziemiecki Ryan,Andrews Elizabeth B.
Funder
Shire Pharmaceuticals GmbH, now part of the Takeda group of companies
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference21 articles.
1. EMA. Resolor (prucalopride). European Medicines Agency. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001012/human_med_001030.jsp&mid=WC0b01ac058001d124. Accessed 12 Nov 2020.
2. Gilsenan A, Fortuny F, Cainzos-Achirica M, Cantero AF, Flynn RWV, Garcia-Rodriguez L, et al. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019;42:1179–90.
3. Fortuny F, Gilsenan A, Cainzos-Achirica M, Cantero AF, Flynn RWV, Garcia-Rodriguez L, et al. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350. Drug Saf. 2019;42:1167–77.
4. ENCePP. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort (EUPAS9200). European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. 2018. http://www.encepp.eu/encepp/viewResource.htm?id=22643. Accessed 12 Nov 2020.
5. Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf. 2008;17:842–52.